<?xml version="1.0"?>
<trials subjects="1">
  <Triall>
    <main>
      <UTRN />
      <trial_id>ChiCTR-INR-17011765</trial_id>
      <utrn />
      <reg_name>ChiCTR</reg_name>
      <date_registration>2017-06-26</date_registration>
      <primary_sponsor>Tianjin First Central Hospital</primary_sponsor>
      <public_title>Clinical study of human umbilical cord blood mesenchymal stem cells in the treatment of refractory lupus nephritis</public_title>
      <acronym />
      <scientific_title>Clinical study of human umbilical cord blood mesenchymal stem cells in the treatment of refractory lupus nephritis</scientific_title>
      <Scientific_acronym />
      <date_enrolment>2017-08-01</date_enrolment>
      <type_enrolment />
      <target_size>MSCs infusion group:15;control group:15;</target_size>
      <recruitment_status>Pending</recruitment_status>
      <url>http://www.chictr.org.cn/showproj.aspx?proj=20065</url>
      <study_type>Interventional study</study_type>
      <study_design>Randomized parallel controlled trial</study_design>
      <phase>New Treatment Measure Clinical Study</phase>
      <hc_freetext>lupus nephritis</hc_freetext>
      <i_freetext>MSCs infusion group:On the basis of conventional doses of corticosteroids + immunosuppressive agents, four 1*10^7/Kg UC MSCs (first, seventh, and six months after the first and seventh days) were administered;control group:Routine dose of glucocorticoid + immunosuppressive agent;</i_freetext>
      <results_actual_enrolment />
      <results_date_completed />
      <results_url_link />
      <results_summary />
      <results_date_posted />
      <results_date_first_publication />
      <results_baseline_char />
      <results_participant_flow />
      <results_adverse_events />
      <results_outcome_measures />
      <results_url_protocol />
      <results_IPD_plan />
      <results_IPD_description />
    </main>
    <contacts>
      <contact>
        <type>Scientific</type>
        <firstname>Shen Peng</firstname>
        <middlename />
        <lastname />
        <address>24 Fukang Road, Nankai District, Tianjin, China</address>
        <city />
        <country1 />
        <zip />
        <telephone>+86 13820789789</telephone>
        <email>shenpm@163.com</email>
        <affiliation>Tianjin First Central Hospital</affiliation>
      </contact>
      <contact>
        <type>Public</type>
        <firstname>Qi Wufang</firstname>
        <middlename />
        <lastname />
        <address>24 Fukang Road, Nankai District, Tianjin, China</address>
        <city />
        <country1 />
        <zip />
        <telephone>+86 13702061222</telephone>
        <email>13702061222@163.com</email>
        <affiliation>Tianjin First Central Hospital</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>China</country2>
    </countries>
    <criteria>
      <inclusion_criteria>SLE patients met the following criteria:
1. meet the American College of Rheumatology 1997 revised SLE classification diagnostic criteria, aged 16~70 years old;
2. lupus nephritis (LN), urine protein (24h) = 1000mg/24h;
3. dimensional prednisone = 20mg/d; cyclophosphamide (CTX);
4. CTX total cumulative amount of invalid 8~10g refers to patients before a recent treatment (12~18 months) accumulation, or other immunosuppressive agents (cyclosporine A, azathioprine, mycophenolate mofetil etc) is invalid for 3 months.</inclusion_criteria>
      <agemin>16</agemin>
      <agemax>70</agemax>
      <gender>Both</gender>
      <exclusion_criteria>The patient had an infection that was not controlled; the patient had one or more organ failure; pregnancy or breast feeding; rejected mesenchymal stem cell transplantation; could not be followed up</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code />
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword />
    </health_condition_keyword>
    <intervention_code>
      <i_code>;;</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword />
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>24H urinary protein quantitation;WBC;PLT;creatinine;SLEDAI score;</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome />
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name />
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id />
        <issuing_authority />
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Tianjin Health Bureau/ Tianjin First Cental Hospital</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2017-04-25</approval_date>
        <contact_name />
        <contact_address />
        <contact_phone />
        <contact_email />
      </ethics_review>
    </ethics_reviews>
  </Triall>
</trials>